Form 4: Recursion Pharma CFO Ben Taylor Reports Stock Transactions

Recursion Pharmaceuticals CFO Ben Taylor reported the sale of Class A Common Stock, including shares withheld for tax obligations and a sale under a 10b5-1 plan.

Summary

• Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc. (RXRX), reported two transactions involving Class A Common Stock.
• On February 17, 2026, 11,908 shares were disposed of at a price of $3.49 per share to satisfy tax withholding obligations related to the net settlement of restricted stock units.
• Following this tax-related disposition, Taylor beneficially owned 1,208,775 shares.
• On February 18, 2026, an additional 13,426 shares were sold at a price of $3.08 per share.
• This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Taylor on September 30, 2025.
• After both transactions, Taylor's beneficial ownership stands at 1,195,349 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can be a yellow flag, the execution under a pre-planned 10b5-1 plan for tax obligations and diversification makes it less concerning than an unplanned, opportunistic sale.

Positives

• The sale of 13,426 shares was conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates a planned transaction for diversification or liquidity rather than a reaction to immediate, non-public information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived by the market as a signal of reduced confidence in the company's near-term prospects or a desire to diversify away from the stock.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception associated with insider stock sales.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals about a company's health and future prospects. While a 10b5-1 plan mitigates the negative perception of an ad-hoc sale, the overall trend of insider buying or selling across the industry can provide broader context on sector sentiment.

Stakeholder Impact

• Shareholders may interpret the insider sale, even if planned, as a potential signal regarding management's long-term view of the stock, which could influence their investment decisions.

Key Dates

Recommendation

A Form 4 filing detailing insider stock sales, particularly when executed under a pre-arranged 10b5-1 plan and for tax purposes, typically does not warrant a change in investment recommendation. While insider selling can be a minor negative signal, the planned nature of the transaction suggests it's for personal financial management rather than a reaction to new, adverse company-specific information. Investors should 'hold' and monitor broader company performance and market trends for more substantial investment decisions.

Keywords

Recursion Pharmaceuticals, RXRX, Ben R Taylor, CFO, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Beneficial Ownership, Tax Withholding